Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...
Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果